The goal of intrapartum surveillance and its further development is better patient care for both the fetus and the gravida. A normal FHR pattern is usually associated with the delivery of a normal well-oxygenated infant; however, a nonreassuring FHR is not always associated with the delivery of a compromised infant. This situation has led to an increase in unnecessary obstetric interventions in the form of a rising cesarean section rate. Fetal scalp sampling was developed in an attempt to improve the predictive value of electronic FHR monitoring, but because this technique is not widely used, management decisions are frequently made using FHR patterns alone. Much research has been performed in the search for a continuous biochemical measurement of fetal status, including continuous pH, pO2, or pCO2 and various combinations of these methodologies. None of these measurements are used in current clinical practice, mainly owing to technical problems and difficulties associated with the continuous direct measurement of these parameters in fetal blood throughout labor. The promising new field of fetal pulse oximetry has the potential to provide reliable, meaningful, and reproducible data as shown in early cross-sectional studies and more recent longitudinal studies. By identifying developing hypoxia, this technology may reduce the uncertainty associated with electronic FHR monitoring. Fetal pulse oximetry may also provide critical information relating to the detection and management of the hypoxic fetus. Any new method of intrapartum fetal monitoring requires careful evaluation to assess its potential value before its introduction into clinical practice. The use of fetal SpO2 monitoring in the presence of a nonreassuring FHR pattern is being examined in a multicenter randomized controlled trial. This study will address the question of whether supplementary monitoring of fetal SpO2 levels can lead to a reduction in the cesarean section rate for fetal distress. The available data on fetal noninvasive pulse oximetry have been obtained from a combination of well-designed cohort studies (level II-2 evidence) or from earlier multiple time series (level II-3 evidence). The results from the US Multicenter Trial (level I evidence) should provide a significant addition to current evidence. A continuous fetal noninvasive monitor measuring fetal oxygenation directly could lead to an improvement in the sensitivity and specificity of fetal surveillance. This improvement could ultimately result in a reduction in unnecessary interventions by differentiating hypoxic fetuses from nonhypoxic fetuses and, more importantly, may lead to earlier intervention for fetuses in danger of serious compromise.